lenvatinib,pembrolizumab
merck,eisai
['leap002', 'pembro', 'keytruda', 'lenvima', 'hepatocellular', 'lenva', 'eisai', 'merck']
#eisai and #merck rahway, nj, usa present results from phase 3 #leap002 trial evaluating #lenvima (#lenvatinib) plus #keytruda (#pembrolizumab) versus #lenvimamonotherapy in patients with #unresectable #hepatocellularcarcinoma #esmo22 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.